| |  Online-Ressource |
|---|
| Verfasst von: | Munshi, Pashna N. [VerfasserIn]  |
|---|
| | Hamadani, Mehdi [VerfasserIn] |
|---|
| | Kumar, Ambuj [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Friedberg, Jonathan W. [VerfasserIn] |
|---|
| | Dreyling, Martin [VerfasserIn] |
|---|
| | Kahl, Brad [VerfasserIn] |
|---|
| | Jerkeman, Mats [VerfasserIn] |
|---|
| | Kharfan-Dabaja, Mohamed A. [VerfasserIn] |
|---|
| | Locke, Frederick L. [VerfasserIn] |
|---|
| | Shadman, Mazyar [VerfasserIn] |
|---|
| | Hill, Brian T. [VerfasserIn] |
|---|
| | Ahmed, Sairah [VerfasserIn] |
|---|
| | Herrera, Alex F. [VerfasserIn] |
|---|
| | Sauter, Craig S. [VerfasserIn] |
|---|
| | Bachanova, Veronika [VerfasserIn] |
|---|
| | Ghosh, Nilanjan [VerfasserIn] |
|---|
| | Lunning, Matthew [VerfasserIn] |
|---|
| | Kenkre, Vaishalee P. [VerfasserIn] |
|---|
| | Aljurf, Mahmoud [VerfasserIn] |
|---|
| | Wang, Michael [VerfasserIn] |
|---|
| | Maddocks, Kami J. [VerfasserIn] |
|---|
| | Leonard, John P. [VerfasserIn] |
|---|
| | Kamdar, Manali [VerfasserIn] |
|---|
| | Phillips, Tycel [VerfasserIn] |
|---|
| | Cashen, Amanda F. [VerfasserIn] |
|---|
| | Inwards, David J. [VerfasserIn] |
|---|
| | Sureda, Anna [VerfasserIn] |
|---|
| | Cohen, Jonathon B. [VerfasserIn] |
|---|
| | Smith, Sonali M. [VerfasserIn] |
|---|
| | Carlo-Stella, Carmello [VerfasserIn] |
|---|
| | Savani, Bipin [VerfasserIn] |
|---|
| | Robinson, Stephen P. [VerfasserIn] |
|---|
| | Fenske, Timothy S. [VerfasserIn] |
|---|
| Titel: | American society of transplantation and cellular therapy, center of international blood and marrow transplant research, and European society for blood and marrow transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma |
|---|
| Verf.angabe: | Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick L. Locke, Mazyar Shadman, Brian T. Hill, Sairah Ahmed, Alex F. Herrera, Craig S. Sauter, Veronika Bachanova, Nilanjan Ghosh, Matthew Lunning, Vaishalee P. Kenkre, Mahmoud Aljurf, Michael Wang, Kami J. Maddocks, John P. Leonard, Manali Kamdar, Tycel Phillips, Amanda F. Cashen, David J. Inwards, Anna Sureda, Jonathon B. Cohen, Sonali M. Smith, Carmello Carlo-Stella, Bipin Savani, Stephen P. Robinson, Timothy S. Fenske |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 24 August 2021 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 11.11.2021 |
|---|
| Titel Quelle: | Enthalten in: Transplantation and cellular therapy |
|---|
| Ort Quelle: | [Amsterdam] : Elsevier B. V., 2021 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 27(2021), 9 vom: Sept., Seite 720-728 |
|---|
| ISSN Quelle: | 2666-6367 |
|---|
| Abstract: | Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated, with a few key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting, the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Several recommendations were based on expert opinion, where the panel developed consensus statements for important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL. |
|---|
| DOI: | doi:10.1016/j.jtct.2021.03.001 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1016/j.jtct.2021.03.001 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S2666636721007442 |
|---|
| | DOI: https://doi.org/10.1016/j.jtct.2021.03.001 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Allogeneic transplantation |
|---|
| | Autologous transplantation |
|---|
| | CAR T cell |
|---|
| | Cellular therapy |
|---|
| | Consensus |
|---|
| | Mantle cell lymphoma |
|---|
| K10plus-PPN: | 1777247535 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
American society of transplantation and cellular therapy, center of international blood and marrow transplant research, and European society for blood and marrow transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma / Munshi, Pashna N. [VerfasserIn]; 24 August 2021 (Online-Ressource)
